Marimed Inc. in brief
Marimed Inc. is a listed company in the Pharmaceutical industry, based in Norwood, Massachusetts, USA. Its last known market value was $138 M (July 2023); there is no current figure. In the year to December 2025 it had sales of $160 M and a net loss of $14 M. Its largest product and service lines by sales in 2025 were Product sales - retail (56%) and Product sales - wholesale (44%).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Marimed Inc.
MariMed Inc designs, develops, operations and financing of new cannabis cultivation centers and dispensaries nationwide. The company annual revenue is 50.8 million USD, annual operating income is 15.5 million USD and total assets are 76.4 million USD as on 2020. The headquarters is in USA.
Marimed Inc. timeline
- 2011
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2017
- ✎Renamed Marimed Inc.Formerly Worlds Online Inc..
- 2022
- 💰Record net income of $13 millionFY2022, the highest profit of the 3 years on record.
- 2025
- 💰Record revenue of $160 millionFY2025, the highest of the 8 years on record.
Events of Marimed Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,492 (Jan 2022) · #4,067 (Dec 2022) · #3,919 (Jul 2023)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- —
- Price / book
- —
- Free cash flow yield
- —
- Net margin (TTM)
- -9.1%
- Operating margin
- -1.8%
- Return on equity
- -29.9%
- Liabilities / assets
- 68.0%
- Net debt
- $67M
- Revenue growth
- +1.3%
- R&D / revenue
- 7.1%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $160M | +1.3% | $-3M | $-14M | -9.1% |
| Dec 2024 | $158M | +6.1% | $3M | $-12M | -7.9% |
| Dec 2023 | $149M | +10.9% | $14M | $-16M | -10.8% |
| Dec 2022 | $134M | +10.3% | $20M | $13M | 10.1% |
| Dec 2021 | $121M | +138.6% | $27M | $7M | 5.9% |
| Dec 2020 | $51M | +11.6% | $15M | $2M | 4.2% |
| Dec 2019 | $46M | +284.8% | $-42M | $-81M | -178.0% |
| Dec 2018 | $12M | — | $-5M | $-14M | -114.8% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $8M | $1M | $7M | $-0.04 | — |
| Dec 2024 | $7M | $12M | $-5M | $-0.03 | — |
| Dec 2023 | $8M | $20M | $-12M | $-0.04 | — |
| Dec 2022 | $7M | $12M | $-5M | $0.04 | — |
| Dec 2021 | $36M | $18M | $18M | $0.02 | — |
| Dec 2020 | $3M | $5M | $-1M | $0.01 | — |
| Dec 2019 | $-24M | $10M | $-34M | $-0.39 | — |
| Dec 2018 | $-3M | $9M | $-12M | $-0.07 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $44M (+8.5% on a year earlier), net income $-4M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.
SEC filings
- Nov 12, 20268-KCurrent reportResults of operations
- Oct 29, 20268-KCurrent reportShareholder vote · Other events
- Sep 23, 20268-KCurrent reportOther events
- Sep 22, 2026DEF 14AProxy statement
- Aug 13, 202610-QQuarterly report · period to Jun 2026
- Aug 12, 20268-KCurrent reportResults of operations
- Jun 8, 20268-KCurrent reportShareholder vote
- May 14, 202610-QQuarterly report · period to Mar 2026
- May 13, 20268-KCurrent reportResults of operations
- Apr 23, 2026DEF 14AProxy statement
- Mar 12, 202610-KAnnual report · period to Dec 2025
- Mar 11, 20268-KCurrent reportResults of operations
Official filings of Marimed Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $160 M
- Operating income
- $-3 M
- Net income
- $-14 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $203 M
- Total liabilities
- $138 M
- Total equity
- $50 M
As of December-2025
Top 1 institutional investors in Marimed Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Game Plan Financial Advisors, LLC | 100 | 0 (0.00%) | 0.00% | $0 M | Nov 10, 2026 |
Insider trading at Marimed Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Jon R. LevinePresident and CEO, Director, 10% owner | Option exercise | +75,000 | — | — | 21.46 M | Form 4 |
| filed | Jon R. LevinePresident and CEO, Director, 10% owner | Shares withheld for tax | -22,013 | $0.067 | $1 K | 21.44 M | Form 4 |
| filed | Jon R. LevinePresident and CEO, Director, 10% owner | Option exercise | +30,625 | — | — | 21.40 M | Form 4 |
| filed | Timothy ShawChief Operating Officer | Option exercise | +42,657 | — | — | 9.50 M | Form 4 |
| filed | Ryan CrandallChief Commercial Officer | Option exercise | +32,812 | — | — | 1.16 M | Form 4 |
| filed | Mario PinhoChief Financial Officer | Option exercise | +38,282 | — | — | 373,454 | Form 4 |
| filed | Mario PinhoChief Financial Officer | Shares withheld for tax | -11,236 | $0.060 | $674 | 362,218 | Form 4 |
| filed | Ryan CrandallChief Commercial Officer | Shares withheld for tax | -9,631 | $0.060 | $578 | 1.15 M | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Marimed Inc. scorecard#
Passes 5 of the 16 checks that could be worked out: strongest in growth (4 of 6), weakest in profitability (0 of 5). Fiscal year 2025.
Valuationnot known
- –P/E below its peers' medianNo market cap.
- –Price to book below its peers' medianNo market cap.
- –Price to sales below its peers' medianNo market cap.
- –Free cash flow yield above 5%No market cap.
- –Earnings yield above the 10-year Treasury yieldNo market cap.
- –The price assumes slower growth than the last three years'No market cap.
Growth4 of 6
- ✓Revenue grew in the newest year1.3%Revenue up 1.3% in fiscal 2025.
- ✓Revenue up more than 5% a year over three years6.0%6.0% a year over the three years to fiscal 2025.
- ✓Faster growth over three years than its peers' median6.0%6.0% a year against Pharmaceutical's median of 2.5% (65 companies).
- ✗Earnings per share grew in the newest year-0.04 vs -0.03Diluted EPS -0.04 in fiscal 2025 against -0.03 the year before (report's currency).
- ✗Net income higher than five years earlier-$14 M-$14 M in fiscal 2025 against $2 M in 2020.
- ✓Revenue rose in at least four of the last five years5 of 5Revenue rose in 5 of the five years to fiscal 2025.
Profitability0 of 5
- ✗Profitable in the newest year-$14 MNet income -$14 M in fiscal 2025.
- ✗Profitable in each of the last five years2 of 5Profitable in 2 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-1.8%-1.8% against Pharmaceutical's median of 1.8% (74 companies).
- ✗Return on equity above 15%-26.7%-26.7% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- ✗Operating margin wider than three years earlier-1.8%-1.8% in fiscal 2025 against 15.2% in 2022.
Financial health1 of 4
- ✗Short-term assets cover short-term liabilities1.0×Current ratio 1.00 at the end of fiscal 2025.
- ✗Debt below equity1.5×Debt to equity 1.52 at the end of fiscal 2025.
- ✗Net debt below three years of EBITDA12.7×Net debt 12.7 times EBITDA in fiscal 2025.
- –Operating income covers interest five timesInterest expense is not on file.
- ✓Cash from operations positive in each of the last three years3 of 3Positive in 3 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year2.9%Diluted shares up 2.9% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueNo market cap.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Pharmaceutical, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Marimed Inc.'s statements, beside the median of Pharmaceutical.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -1.8% | 1.8% | |
| Net margin | -9.1% | -1.5% | |
| Return on equity | -26.7% | -0.9% | |
| Revenue growth, 3 years a year | 6.1% | 2.5% | |
| Revenue growth | 1.3% | 7.3% | |
| Debt to equity | 1.52× | 0.66× |
4of 9on the Piotroski tests of financial strength
- Net loss of $14 million, the 3th loss-making year in a row.
- Net debt is 12.7 times a year's operating earnings before depreciation.
- Revenue has grown 11 years in a row.
Marimed Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 160+1.3%100% | 158r158+6.1%100% | 149+10.9%100% | 134+10.3%100% | 121r121+139%100% | 51+11.6%100% | 46+285%100% | 12+95.3%100% | 6.1+70.2%100% | 3.6—100% | |
| Cost of revenue | 102+7.2%63.8% | 95+15.0%60.3% | 83+18.0%55.6% | 70+26.9%52.3% | 55r55+182%45.4% | 20−27.3%38.5% | 27+566%59.0% | 4.0+84.3%34.1% | 2.2r2.6+62.2%36.1% | 1.4—37.9% | |
| Gross profit | 58−7.6%36.2% | 63r63−5.0%39.7% | 66+3.1%44.4% | 64−3.5%47.7% | 66r66+112%54.6% | 31+67.5%61.5% | 19+139%41.0% | 7.8+102%65.9% | 3.9r3.5+99.1%63.9% | 1.9r2.2—54.6% | |
| Selling, general and administrative | — | — | — | — | — | — | — | — | — | 0.8—21.6% | |
| General and administrative | 26+2.0%16.4% | 26+15.8%16.2% | 22+6.7%14.9% | 21−24.8%15.5% | 28r28+178%22.7% | 9.9+12.3%19.5% | 8.8r8.9−12.3%19.3% | 10r10+249%84.8% | 2.9r1.4+342%47.5% | 0.7—18.3% | |
| Operating expenses | 61+1.2%38.0% | 60r60+16.4%38.0% | 52+18.2%34.7% | 44+10.6%32.5% | 39r39+135%32.4% | 17−72.1%33.0% | 60r60+357%132% | 13+251%111% | 3.7r2.3+220%61.8% | 1.2r1.6—32.9% | |
| Operating income | −2.8−208%−1.8% | 2.6r2.9−81.9%1.7% | 14−29.4%9.7% | 20−24.2%15.2% | 27r27+84.9%22.1% | 15—28.6% | −42r−42—−91.1% | −5.4−4296%−45.2% | 0.1r1.2−83.5%2.1% | 0.8r0.6—21.8% | |
| Interest expense and finance costs | 7.5+8.0%4.7% | 6.9−24.4%4.4% | 9.2+443%6.2% | 1.7−28.1%1.3% | 2.4r2.4−76.0%1.9% | 9.8−22.9%19.3% | 13+191%27.9% | 4.4+637%36.8% | 0.6r−0.5—9.8% | −0.3r−0.3—−8.2% | |
| Net interest income | — | — | — | — | — | — | — | — | — | 0.1—1.6% | |
| Share of profit of associates | — | — | — | — | — | 0.1—0.2% | −30—−66.5% | −0.0—−0.4% | — | — | |
| Other non-operating income (expense) | −8.0—−5.0% | −6.9—−4.4% | −21—−14.1% | −0.9—−0.6% | −3.0r−3.0—−2.5% | −10—−19.7% | −40—−88.3% | −8.0r8.0−788%−67.1% | 1.2r2.2+155%19.1% | 0.5—12.7% | |
| Income before tax | −11—−6.8% | −4.3r−4.0—−2.7% | −6.6−134%−4.4% | 20−18.1%14.6% | 24r24+430%19.6% | 4.5—8.8% | −82—−179% | — | — | — | |
| Income tax | 3.6−56.0%2.2% | 8.2−13.3%5.2% | 9.4+59.7%6.3% | 5.9−63.6%4.4% | 16r16+683%13.3% | 2.1+2978%4.1% | 0.1—0.1% | — | — | — | |
| Net income including minority interests | −14—−9.0% | −12r−12—−7.9% | −16−218%−10.8% | 14+78.6%10.2% | 7.6r7.6+214%6.3% | 2.4—4.8% | −82—−180% | −13—−112% | −1.0−420%−17.0% | 0.3r−0.2—9.0% | |
| Minority interests' share of net income | 0.0−24.3%0.0% | 0.0+54.2%0.0% | 0.0−83.6%0.0% | 0.1−63.4%0.1% | 0.4r0.4+39.9%0.3% | 0.3—0.6% | −0.7−336%−1.5% | 0.3+79.0%2.5% | 0.2−68.3%2.7% | 0.5—14.6% | |
| Net income attributable to shareholders | −14—−9.1% | −12r−12—−7.9% | −16−219%−10.8% | 13+86.4%10.0% | 7.2r7.2+237%5.9% | 2.1—4.2% | −81—−178% | −14—−115% | −1.2—−19.7% | −0.2r0.3—−5.6% | |
| Earnings per share, basic | -0.04—— | -0.03—— | -0.04−200%— | 0.04+100%— | 0.02+100%— | 0.01—— | -0.39—— | -0.07r-0.07—— | -0.01—— | -0.00—— | |
| Earnings per share, diluted | -0.04—— | -0.03—— | -0.04−200%— | 0.04+100%— | 0.02+100%— | 0.01—— | -0.39—— | -0.07r-0.07—— | -0.01—— | -0.00—— | |
| Shares, weighted average (basic) | 390+2.9%— | 379+4.3%— | 363+7.6%— | 338+3.4%— | 326r326+22.3%— | 267+27.9%— | 209—— | — | — | 52—— | |
| Shares, weighted average (diluted) | 390+2.9%— | 379+4.3%— | 363−4.4%— | 380+2.1%— | 372r372+14.9%— | 324+55.3%— | 209+8.5%— | 192+65.4%— | 116+124%— | 52—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 8.9+22.0%4.4% | 7.3−50.3%3.5% | 15+50.4%7.5% | 9.7−67.2%6.4% | 30r30+890%24.1% | 3.0+306%3.9% | 0.7−82.0%1.2% | 4.1+218%4.9% | 1.3+127%4.0% | 0.6—6.6% | |
| Short-term investments | — | 0−100%0.0% | 0.1−28.5%0.0% | 0.1−51.0%0.1% | 0.3r0.3−81.5%0.2% | 1.4−6.3%1.8% | 1.4—2.4% | — | — | — | |
| Receivables | 9.1+4.3%4.5% | 8.7+21.4%4.2% | 7.2+73.2%3.7% | 4.2+150%2.7% | 1.7r1.7−75.0%1.4% | 6.7+300%8.7% | 1.7−69.0%2.7% | 5.4+270%6.5% | 1.5+173%4.5% | 0.5—6.2% | |
| Inventory | 37+9.3%18.1% | 33+32.3%16.2% | 25+29.9%12.9% | 19+99.4%12.8% | 9.8r9.8+43.0%7.9% | 6.8+460%8.9% | 1.2+1248%2.0% | 0.1—0.1% | — | — | |
| Other current assets | 3.8+12.9%1.9% | 3.4−3.5%1.6% | 3.5r3.4−51.8%1.8% | 7.3+406%4.8% | 1.4r1.4+147%1.2% | 0.6+203%0.8% | 0.2+49.6%0.3% | 0.1r0.2−64.0%0.2% | 0.4+2131%1.1% | 0.0r0.2—0.2% | |
| Current assets | 59+10.8%29.3% | 54+4.0%25.9% | 51+16.5%26.2% | 44−1.0%29.0% | 45r45+112%36.2% | 21+185%27.5% | 7.4−53.0%12.0% | 16+216%18.9% | 5.0r5.1+104%15.4% | 2.4r2.7—28.5% | |
| Property, plant and equipment | 89−5.1%44.1% | 94+5.7%45.5% | 89+24.4%45.4% | 72+15.3%47.1% | 62r62+36.2%50.4% | 46+6.6%59.7% | 43+25.5%69.5% | 34+31.4%41.1% | 26+389%80.6% | 5.3r5.3—62.0% | |
| Right-of-use (leased) assets | 7.7−11.5%3.8% | 8.7−10.1%4.2% | 9.7+97.0%5.0% | 4.9−3.0%3.2% | 5.1r5.1−3.2%4.1% | 5.2−9.3%6.9% | 5.8—9.4% | — | — | — | |
| Goodwill | 24+51.8%11.8% | 16+31.8%7.6% | 12+48.4%6.1% | 8.1+291%5.3% | 2.10.0%1.7% | 2.1r2.1—2.7% | — | — | — | — | |
| Other intangible assets | 17−7.7%8.5% | 19+9.6%9.0% | 17+19.8%8.7% | 14+8666%9.3% | 0.2r2.2−92.7%0.1% | 2.2−5.7%2.9% | 2.4+1178%3.8% | 0.2−44.5%0.2% | 0.3—1.0% | — | |
| Long-term investments | — | 0−100%0.0% | 0.2—0.1% | 0—0.0% | 0−100%0.0% | 1.2−12.0%1.5% | 1.3−20.8%2.2% | 1.7—2.0% | — | — | |
| Total assets | 203−2.1%100% | 207+5.5%100% | 196+28.9%100% | 152+23.5%100% | 123r123+61.2%100% | 76+24.2%100% | 62−25.8%100% | 83+158%100% | 32+276%100% | 8.6r5.8—100% | |
| Accounts payable | 15+10.6%7.2% | 13+46.5%6.4% | 9.0+35.8%4.6% | 6.6+29.9%4.4% | 5.1r5.1+1.1%4.1% | 5.0+6.9%6.6% | 4.7+20.5%7.7% | 3.9+38.3%4.7% | 2.8+500%8.8% | 0.5r0.8—5.5% | |
| Current liabilities | 59+18.1%29.2% | 50r49+62.0%24.2% | 31+16.5%15.7% | 26−2.7%17.4% | 27r27+17.2%22.1% | 23−36.7%30.4% | 37+269%59.6% | 10.0r9.9−35.5%12.0% | 15+152%47.9% | 6.1r7.1—71.5% | |
| Lease liabilities (non-current) | 6.6−12.4%3.3% | 7.5−10.7%3.6% | 8.5+103%4.3% | 4.2−8.8%2.7% | 4.6r4.6−5.1%3.7% | 4.8−10.7%6.3% | 5.4—8.8% | — | — | — | |
| Total liabilities | 138+6.5%68.0% | 129r128+20.7%62.5% | 107+87.5%54.7% | 57+16.2%37.6% | 49r49−8.3%39.9% | 54−2.9%70.1% | 55+161%89.7% | 21+0.0%25.5% | 21+133%65.8% | 9.1r9.1—106% | |
| Retained earnings | −128—−63.2% | −113r−112—−54.8% | −100—−51.0% | −84—−55.1% | −97r−97—−79.0% | −105—−137% | −107—−173% | −26—−30.8% | −12—−37.2% | −11—−126% | |
| Shareholders' equity | — | — | — | — | — | — | — | 62+461%74.5% | 11—34.2% | −0.6r−0.6—−6.4% | |
| Minority interests | −1.9—−0.9% | −1.8—−0.8% | −1.7—−0.8% | −1.5—−1.0% | −1.6r−1.6—−1.3% | −0.6—−0.8% | −0.6—−0.9% | −0.2−225%−0.3% | 0.2−68.5%0.5% | 0.6—6.5% | |
| Total equity | 50−14.6%24.7% | 59r60−15.0%28.3% | 69r70+20.2%35.1% | 57+57.9%37.7% | 36r36+348%29.5% | 8.1r8.1+28.0%10.6% | 6.3−89.8%10.3% | 62+461%74.5% | 11—34.2% | −0.6—−6.4% | |
| Total liabilities and equity | 203−2.1%100% | 207+5.5%100% | 196+28.9%100% | 152+23.5%100% | 123r123+61.2%100% | 76+24.2%100% | 62−25.8%100% | 83+158%100% | 32+276%100% | 8.6—100% | |
| Shares outstanding | 397+4.0%— | 381+1.7%— | 375+9.9%— | 341+2.2%— | 334+6.2%— | 314+37.7%— | 228+8.2%— | 211+19.3%— | 177+176%— | 64—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 8.1+2.5%5.1% | 7.9+42.5%5.0% | 5.5+61.7%3.7% | 3.4—2.6% | — | 1.8+80.0%3.5% | 1.0r1.0+52.0%2.2% | 0.7+81.3%5.6% | 0.4r0.4+36.6%6.0% | 0.3—7.5% | |
| Share-based compensation | 1.9+77.1%1.2% | 1.1+2.9%0.7% | 1.0−83.9%0.7% | 6.3—4.7% | — | — | — | 5.8+434%48.6% | 1.1+559%17.8% | 0.2—4.6% | |
| Cash from operating activities | 7.7+13.4%4.8% | 6.8−14.2%4.3% | 7.9+8.2%5.3% | 7.3−79.6%5.5% | 36r36+961%29.5% | 3.4—6.6% | −24—−52.9% | −2.9−265%−24.5% | 1.8r1.3—29.1% | −0.2r−0.2—−5.6% | |
| Capital expenditure | −1.2—−0.7% | −12—−7.6% | −20—−13.5% | −12—−9.1% | −18r−18—−14.7% | −4.7—−9.2% | −9.7—−21.2% | −8.9—−75.3% | −21r−21—−346% | −3.4—−94.4% | |
| Acquisitions, net of cash acquired | −0.2—−0.1% | −4.3—−2.7% | −3.0—−2.0% | −13—−9.6% | 0—0.0% | — | — | — | — | — | |
| Cash from investing activities | −1.4—−0.9% | −17—−10.9% | −26—−17.5% | −26—−19.6% | −17r−17—−13.7% | −4.5—−8.8% | −13—−27.5% | −40—−338% | −21r−21—−345% | −3.3—−93.7% | |
| Debt issued | — | — | — | — | — | 0.9−90.3%1.8% | 9.6−4.1%21.1% | 10—84.4% | — | — | |
| Shares issued | — | — | — | — | — | — | 2.8−91.4%6.0% | 32+383%268% | 6.6r6.6+1521%109% | 0.4—11.4% | |
| Cash from financing activities | −4.7−258%−2.9% | 3.0−87.0%1.9% | 23—15.5% | −1.0−114%−0.8% | 7.5r7.5+123%6.1% | 3.3−90.0%6.6% | 33−27.3%73.0% | 46+130%386% | 20r20+404%328% | 3.9—111% | |
| Change in cash | 1.6—1.0% | −7.4−250%−4.7% | 4.9—3.3% | −20−175%−14.9% | 27r27+1081%22.0% | 2.3—4.4% | −3.4−220%−7.4% | 2.8+290%23.7% | 0.7+76.5%11.9% | 0.4r0.4—11.5% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 167+6.5%100% | 44+8.5%100% | 42+6.1%100% | 39+4.2%100% | 42*+6.9%100% | 41+0.4%100% | 40r40−2.3%100% | 38r38−0.1%100% | 39r39*+0.1%100% | 41r41—100% | 40—100% | 38—100% | 39*—100% | |
| Cost of revenue | 108+11.4%64.6% | 27+10.9%61.2% | 26+9.0%61.3% | 24+6.1%61.3% | 31*+18.5%74.8% | 24+2.5%59.9% | 24+0.2%59.7% | 23+6.3%60.2% | 26*+21.8%67.5% | 24—58.7% | 24—58.2% | 21—56.6% | 22*—55.5% | |
| Gross profit | 59−1.5%35.4% | 17+4.9%38.8% | 16+1.9%38.7% | 15+1.2%38.7% | 11*−17.0%25.2% | 16−2.5%40.1% | 16r16−5.8%40.3% | 15r15−8.4%39.8% | 13r13*−26.9%32.5% | 17r17—41.3% | 17—41.8% | 16—43.4% | 17*—44.5% | |
| General and administrative | 27+6.4%16.4% | 6.7+1.8%15.2% | 6.9+8.2%16.4% | 6.9+10.2%17.4% | 7.0*+5.8%16.7% | 6.6+8.1%16.2% | 6.3−6.8%16.1% | 6.3+1.8%16.5% | 6.6*−0.6%16.9% | 6.1—15.0% | 6.8—16.8% | 6.1—16.2% | 6.6*—17.0% | |
| Operating expenses | 62+3.6%37.0% | 16+8.0%36.0% | 16+6.0%37.7% | 15−5.3%38.4% | 15*+6.4%36.1% | 15−4.4%36.2% | 15r15−6.5%37.7% | 16r16+10.7%42.2% | 14r14*−5.2%36.3% | 15r15—38.0% | 16—39.5% | 14—38.1% | 15*—38.3% | |
| Operating income | −2.8−1265%−1.7% | 1.2−23.6%2.8% | 0.4−58.9%1.0% | 0.1—0.3% | −4.5*—−10.9% | 1.6+18.9%3.9% | 1.0r1.1+6.3%2.6% | −0.9r−0.9−145%−2.4% | −1.5r−1.4*−161%−3.8% | 1.3r1.3—3.3% | 1.0—2.4% | 2.0—5.3% | 2.4*—6.2% | |
| Interest expense and finance costs | 8.1+12.5%4.9% | 2.0+9.8%4.5% | 2.0+13.9%4.8% | 2.0+12.1%5.0% | 2.2*+14.2%5.2% | 1.8+7.0%4.5% | 1.8+2.2%4.5% | 1.8+8.2%4.6% | 1.9*+21.1%4.8% | 1.7—4.2% | 1.7—4.3% | 1.6—4.3% | 1.6*—4.0% | |
| Other non-operating income (expense) | −8.0—−4.8% | −2.0—−4.4% | −2.0—−4.7% | −1.2—−3.1% | −2.8*—−6.7% | −1.8—−4.4% | −1.7—−4.4% | −1.7—−4.6% | −1.8*—−4.7% | −1.7—−4.1% | −1.7—−4.3% | −1.6—−4.3% | −12*—−31.0% | |
| Income before tax | −11—−6.4% | −0.7—−1.7% | −1.6—−3.7% | −1.1—−2.8% | −7.3*—−17.6% | −0.2—−0.4% | −0.7r−0.6—−1.8% | −2.6r−2.6−765%−7.0% | −3.3r−3.3*—−8.5% | −0.3r−0.3—−0.8% | −0.8—−1.9% | 0.4—1.0% | −9.6*—−24.8% | |
| Income tax | 4.7−57.9%2.8% | 2.7−0.6%6.2% | 2.0+192%4.8% | 2.7−6.4%6.7% | −2.7*−154%−6.5% | 2.8+321%6.8% | 0.7−20.2%1.7% | 2.8+67.5%7.5% | 4.9*+872%12.7% | 0.7—1.6% | 0.9—2.1% | 1.7—4.5% | 0.5*—1.3% | |
| Net income including minority interests | −15—−9.2% | −3.5—−7.9% | −3.6—−8.5% | −3.8—−9.5% | −4.6*—−11.1% | −2.9—−7.2% | −1.4r−1.3—−3.5% | −5.5r−5.4—−14.5% | −8.3r−8.2*—−21.2% | −1.0r−1.0—−2.4% | −1.8r−1.6—−4.4% | −1.4r−1.3—−3.7% | −10*—−26.1% | |
| Minority interests' share of net income | 0.0+7.3%0.0% | 0.0+157%0.0% | 0.0—0.0% | 0.0−43.8%0.0% | −0.0*−433%−0.0% | 0.0−56.3%0.0% | −0.0−108%−0.0% | 0.0+433%0.1% | 0.0*−90.0%0.0% | 0.0—0.0% | 0.0—0.0% | 0.0—0.0% | 0.0*—0.1% | |
| Net income attributable to shareholders | −16—−9.3% | −3.5—−7.9% | −3.6—−8.6% | −3.8—−9.6% | −4.6*—−11.1% | −2.9—−7.2% | −1.4r−1.3—−3.5% | −5.5r−5.5—−14.5% | −8.3r−8.2*—−21.2% | −1.0r−1.0—−2.5% | −1.7—−4.1% | −1.3—−3.4% | −10*—−26.1% | |
| Earnings per share, basic | — | -0.01—— | -0.01—— | -0.01—— | — | -0.01—— | 0.00—— | -0.01—— | — | 0.00—— | 0.00—— | 0.00—— | — | |
| Earnings per share, diluted | — | -0.01—— | -0.01—— | -0.01—— | — | -0.01—— | 0.00—— | -0.01—— | — | 0.00—— | 0.00—— | 0.00—— | — | |
| Shares, weighted average (basic) | 403+2.6%— | 403+2.6%— | 400+2.5%— | 397+3.9%— | — | 393+3.2%— | 390+2.7%— | 383+2.0%— | — | 381—— | 380—— | 375—— | — | |
| Shares, weighted average (diluted) | 403+2.6%— | 403+2.6%— | 400+2.5%— | 397+3.9%— | — | 393+3.2%— | 390+2.7%— | 383+2.0%— | — | 381—— | 380—— | 375—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 10—5.2% | 10+57.1%5.2% | 8.4+37.5%4.3% | 7.9+10.2%3.9% | 8.9+22.0%4.4% | 6.6−32.6%3.2% | 6.1−39.8%3.0% | 7.2−52.7%3.5% | 7.3−50.3%3.5% | 9.8—4.6% | 10—4.9% | 15—7.6% | 15—7.5% | |
| Short-term investments | — | — | — | — | — | — | — | — | 0−100%0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0.1—0.0% | |
| Receivables | 9.2—4.6% | 9.2+15.3%4.6% | 9.4+21.7%4.7% | 9.4+2.8%4.7% | 9.1+4.3%4.5% | 8.0+8.7%3.9% | 7.7−0.7%3.8% | 9.2+41.5%4.4% | 8.7+21.4%4.2% | 7.3—3.4% | 7.7—3.7% | 6.5—3.2% | 7.2—3.7% | |
| Inventory | 38—18.9% | 38−6.2%18.9% | 37−5.5%18.6% | 39+4.6%19.5% | 37+9.3%18.1% | 40+14.5%19.5% | 39+24.7%19.0% | 38+29.3%18.1% | 33+32.3%16.2% | 35—16.4% | 31—14.9% | 29—14.4% | 25—12.9% | |
| Other current assets | 4.3—2.1% | 4.3−8.3%2.1% | 4.0−10.9%2.0% | 3.3−18.9%1.6% | 3.8+12.9%1.9% | 4.6+26.4%2.3% | 4.4+43.2%2.2% | 4.0+22.1%1.9% | 3.4−3.5%1.6% | 3.7—1.7% | 3.1—1.5% | 3.3—1.6% | 3.5r3.4—1.8% | |
| Current assets | 61—30.9% | 61+2.1%30.9% | 58+2.3%29.6% | 61+4.8%30.2% | 59+10.8%29.3% | 60+6.0%29.2% | 57+7.7%28.0% | 58+5.7%27.9% | 54+4.0%25.9% | 57—26.7% | 53—25.4% | 55—27.3% | 51—26.2% | |
| Property, plant and equipment | 85—42.8% | 85−6.9%42.8% | 86−6.7%43.8% | 88−6.7%43.8% | 89−5.1%44.1% | 91−4.4%44.4% | 93−1.4%45.3% | 94+4.0%45.4% | 94+5.7%45.5% | 95—44.9% | 94—45.1% | 91—45.1% | 89—45.4% | |
| Right-of-use (leased) assets | 8.4—4.2% | 8.4+5.7%4.2% | 7.7−7.1%3.9% | 7.5−11.6%3.7% | 7.7−11.5%3.8% | 8.0−11.2%3.9% | 8.3−10.5%4.0% | 8.5−9.8%4.1% | 8.7−10.1%4.2% | 9.0—4.2% | 9.2—4.4% | 9.5—4.7% | 9.7—5.0% | |
| Goodwill | 24—12.1% | 24+5.9%12.1% | 24+19.7%12.2% | 24+23.2%11.9% | 24+51.8%11.8% | 23+43.3%11.0% | 20+26.8%9.8% | 19+23.2%9.4% | 16+31.8%7.6% | 16—7.4% | 16—7.6% | 16—7.9% | 12—6.1% | |
| Other intangible assets | 15—7.5% | 15−16.9%7.5% | 16−24.3%8.0% | 16−24.4%8.2% | 17−7.7%8.5% | 18−7.7%8.8% | 21+1.6%10.1% | 22+69.2%10.4% | 19+9.6%9.0% | 20—9.2% | 20—9.8% | 13—6.4% | 17—8.7% | |
| Long-term investments | — | — | — | — | — | — | — | — | 0−100%0.0% | 0—0.0% | 0—0.0% | 0.3—0.1% | 0.2—0.1% | |
| Total assets | 198—100% | 198−3.5%100% | 197−3.5%100% | 201−3.3%100% | 203−2.1%100% | 206−3.3%100% | 204−2.0%100% | 208+3.3%100% | 207+5.5%100% | 213—100% | 209—100% | 201—100% | 196—100% | |
| Accounts payable | 15—7.5% | 15+32.4%7.5% | 13+17.2%6.7% | 15+8.2%7.5% | 15+10.6%7.2% | 11−13.4%5.5% | 11−5.4%5.5% | 14+36.2%6.7% | 13+46.5%6.4% | 13—6.1% | 12—5.7% | 10—5.1% | 9.0—4.6% | |
| Current liabilities | 68—34.3% | 68+20.1%34.3% | 64+25.1%32.3% | 64+15.3%31.7% | 59+18.1%29.2% | 57+26.9%27.5% | 51+25.3%24.9% | 55+56.0%26.6% | 50r49+62.0%24.2% | 45—21.0% | 41—19.5% | 35—17.6% | 31—15.7% | |
| Lease liabilities (non-current) | 7.2—3.6% | 7.2+5.4%3.6% | 6.5−8.0%3.3% | 6.4−12.1%3.2% | 6.6−12.4%3.3% | 6.8−12.2%3.3% | 7.0−12.0%3.4% | 7.3−11.5%3.5% | 7.5−10.7%3.6% | 7.8—3.7% | 8.0—3.8% | 8.2—4.1% | 8.5—4.3% | |
| Total liabilities | 151—76.3% | 151+10.8%76.3% | 147+12.1%74.6% | 148+10.2%73.4% | 138+6.5%68.0% | 137+8.5%66.4% | 131+8.5%64.2% | 134+18.1%64.5% | 129r128+20.7%62.5% | 126—59.2% | 121—58.0% | 114—56.4% | 107—54.7% | |
| Retained earnings | −139—−70.0% | −139—−70.0% | −135—−68.6% | −132—−65.5% | −128—−63.2% | −123—−60.0% | −119—−58.1% | −118—−56.5% | −113r−112—−54.8% | −104—−48.9% | −103—−49.3% | −101—−50.3% | −100—−51.0% | |
| Minority interests | −1.9—−1.0% | −1.9—−1.0% | −1.9—−1.0% | −1.9—−0.9% | −1.9—−0.9% | −1.8—−0.9% | −1.8—−0.9% | −1.8—−0.9% | −1.8—−0.8% | −1.7—−0.8% | −1.7—−0.8% | −1.7—−0.8% | −1.7—−0.8% | |
| Total equity | 40—20.2% | 40−26.3%20.2% | 43−24.0%21.9% | 47−19.6%23.1% | 50−14.6%24.7% | 54−18.4%26.4% | 57r58−15.4%27.9% | 58r59−14.6%27.8% | 59r60−15.0%28.3% | 67r68—31.3% | 67r69—32.3% | 68r69—33.6% | 69r70—35.1% | |
| Total liabilities and equity | 198—100% | 198−3.5%100% | 197−3.5%100% | 201−3.3%100% | 203−2.1%100% | 206−3.3%100% | 204−2.0%100% | 208+3.3%100% | 207+5.5%100% | 213—100% | 209—100% | 201—100% | 196—100% | |
| Shares outstanding | 405—— | 405+2.6%— | 401+2.3%— | 399+2.6%— | 397+4.0%— | 394+3.5%— | 392+3.1%— | 389+3.5%— | 381+1.7%— | 381—— | 380—— | 375—— | 375—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 8.8+6.8%5.2% | 2.2*+4.1%5.0% | 2.3*+10.3%5.6% | 2.2+19.1%5.5% | 2.1*−4.1%5.0% | 2.1*+17.3%5.2% | 2.1*+5.3%5.4% | 1.8−6.8%4.8% | 2.2*+26.3%5.5% | 1.8*—4.4% | 2.0*—5.0% | 1.9—5.1% | 1.7*—4.4% | |
| Share-based compensation | 1.4−20.7%0.8% | 0.3*−12.3%0.8% | 0.4*−36.2%0.8% | 0.3−40.6%0.8% | 0.4*+37.4%0.9% | 0.4*+36.4%0.9% | 0.5*+121%1.4% | 0.5+124%1.4% | 0.3*+26.9%0.7% | 0.3*—0.7% | 0.2*—0.6% | 0.2—0.6% | 0.2*—0.6% | |
| Cash from operating activities | 10+162%6.0% | 3.5*+30.3%7.9% | 2.2*+647%5.3% | 0.9−26.6%2.4% | 3.4*—8.2% | 2.7*+233%6.6% | 0.3*−90.7%0.8% | 1.3−59.7%3.4% | −0.4*−113%−1.1% | 0.8*—2.0% | 3.2*—7.9% | 3.2—8.5% | 3.2*—8.3% | |
| Capital expenditure | −0.9—−0.6% | −0.2*—−0.6% | −0.3*—−0.7% | −0.4—−0.9% | −0.0*—−0.1% | −0.6*—−1.4% | −0.3*—−0.8% | −0.3—−0.7% | −1.1*—−2.7% | −2.6*—−6.3% | −5.0*—−12.3% | −3.4—−8.9% | −5.4*—−13.8% | |
| Acquisitions, net of cash acquired | 0—0.0% | 0*—0.0% | 0*—0.0% | 0—0.0% | 0*—0.0% | 0*—0.0% | 0*—0.0% | −0.2—−0.6% | 0*—0.0% | 0*—0.0% | −4.3*—−10.5% | 0—0.0% | 0*—0.0% | |
| Cash from investing activities | −1.8—−1.0% | −0.3*—−0.7% | −0.5*—−1.2% | −0.8—−1.9% | −0.2*—−0.5% | −0.5*—−1.3% | −0.6*—−1.4% | −0.1—−0.3% | −1.2*—−3.1% | −2.1*—−5.2% | −9.5*—−23.6% | −4.3—−11.2% | −6.3*—−16.3% | |
| Cash from financing activities | −4.6—−2.7% | −1.3*—−2.9% | −1.2*—−2.9% | −1.1—−2.9% | −0.9*—−2.3% | −1.7*−286%−4.2% | −0.8*−161%−2.0% | −1.3−177%−3.3% | −0.9*−120%−2.3% | 0.9*—2.3% | 1.3*—3.3% | 1.6—4.3% | 4.5*—11.6% | |
| Change in cash | 3.8—2.3% | 1.9*+320%4.4% | 0.5*—1.2% | −0.9—−2.4% | 2.3*—5.5% | 0.5*—1.1% | −1.1*—−2.7% | −0.1−114%−0.2% | −2.5*−281%−6.4% | −0.4*—−1.0% | −5.0*—−12.5% | 0.6—1.6% | 1.4*—3.6% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Marimed Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Product sales - retail$89 M56%-2.5%
- Product sales - wholesale$70 M44%+11%
- Other revenue$1 M0.8%-66%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Events at Marimed Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 2 · Material agreement 2 · New debt 2 · Unregistered share sale 1 · Bylaws or fiscal year changed 1 · Shareholder vote 4 · Results announced 14
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreementNew debtUnregistered share saleBylaws or fiscal year changed | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreementNew debt | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
3 acquisitions, $19 M paid where reported
Businesses it acquired
| Acquired | Acquisition date | Completion | Price | Stake | Source |
|---|---|---|---|---|---|
| First State Compassion Center | 2025 | — | $11 M | 100% | Annual report |
| Wellness & Compassionate Care Center, Inc | 2024 | — | $5 M | 100% | Annual report |
| Allgreens Dispensary LLC | 2022 | — | $2 M | — | Annual report |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
How Marimed Inc. compares in Pharmaceutical
- Revenue$160 M · higher than 26% of 324
- Net margin-9.1% · higher than 19% of 313
- Revenue growth1.3% · higher than 31% of 107
Peer comparison · Pharmaceutical
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Marimed Inc.🇺🇸 | $138 M | — | -9.1% | +1.3% |
| Eli Lilly and Company🇺🇸 | $1.20 T | 43.4× | 31.9% | +44.7% |
| Johnson & Johnson🇺🇸 | $652.5 B | 40.5× | 16.2% | +6.0% |
| AbbVie Inc.🇺🇸 | $514.0 B | 49.7× | 15.7% | +8.6% |
| Roche Holding AG🇨🇭 | $370.3 B | 29.1× | 19.0% | — |
| Merck & Co., Inc.🇺🇸 | $359.8 B | 146.7× | 3.6% | +1.3% |
| Novartis AG🇨🇭 | $286.8 B | 20.5× | 24.7% | — |
| Amgen Inc.🇺🇸 | $249.2 B | 26.5× | 24.1% | +9.9% |
| AstraZeneca PLC🇬🇧 | $242.6 B | 23.7× | 17.4% | +8.6% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Eli Lilly and Company$1.20 T
- Johnson & Johnson$652.5 B
- AbbVie Inc.$514.0 B
- Roche Holding AG$370.3 B
- Merck & Co., Inc.$359.8 B
- Novartis AG$286.8 B
Sources and freshness
- Market cap:
- Jul 30, 2023 (last known)
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 16, 2026
Figures from SEC filing, value.today research; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Marimed Inc.? Verify and update this profile — free
Show Marimed Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.